Abstract
BackgroundAdjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have